1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by IBS-C Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global IBS-C Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Linaclotide
1.4.3 Lubiprostone
1.4.4 Osmotic Laxatives
1.4.5 Stimulant Laxatives
1.4.6 Other
1.5 Market by Application
1.5.1 Global IBS-C Drug Market Share by Application: 2021-2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global IBS-C Drug Market
1.8.1 Global IBS-C Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global IBS-C Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global IBS-C Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global IBS-C Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers IBS-C Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global IBS-C Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global IBS-C Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America IBS-C Drug Sales Volume
3.3.1 North America IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia IBS-C Drug Sales Volume
3.4.1 East Asia IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe IBS-C Drug Sales Volume (2015-2020)
3.5.1 Europe IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia IBS-C Drug Sales Volume (2015-2020)
3.6.1 South Asia IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia IBS-C Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East IBS-C Drug Sales Volume (2015-2020)
3.8.1 Middle East IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa IBS-C Drug Sales Volume (2015-2020)
3.9.1 Africa IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania IBS-C Drug Sales Volume (2015-2020)
3.10.1 Oceania IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America IBS-C Drug Sales Volume (2015-2020)
3.11.1 South America IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World IBS-C Drug Sales Volume (2015-2020)
3.12.1 Rest of the World IBS-C Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World IBS-C Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America IBS-C Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia IBS-C Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe IBS-C Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia IBS-C Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia IBS-C Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East IBS-C Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa IBS-C Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania IBS-C Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America IBS-C Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World IBS-C Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global IBS-C Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global IBS-C Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global IBS-C Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global IBS-C Drug Consumption Volume by Application (2015-2020)
15.2 Global IBS-C Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in IBS-C Drug Business
16.1 Catalent Pharmaceuticals Solutions
16.1.1 Catalent Pharmaceuticals Solutions Company Profile
16.1.2 Catalent Pharmaceuticals Solutions IBS-C Drug Product Specification
16.1.3 Catalent Pharmaceuticals Solutions IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Ardelyx
16.2.1 Ardelyx Company Profile
16.2.2 Ardelyx IBS-C Drug Product Specification
16.2.3 Ardelyx IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Synergy Pharmaceuticals
16.3.1 Synergy Pharmaceuticals Company Profile
16.3.2 Synergy Pharmaceuticals IBS-C Drug Product Specification
16.3.3 Synergy Pharmaceuticals IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Nestle
16.4.1 Nestle Company Profile
16.4.2 Nestle IBS-C Drug Product Specification
16.4.3 Nestle IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Astellas Pharmaceuticals
16.5.1 Astellas Pharmaceuticals Company Profile
16.5.2 Astellas Pharmaceuticals IBS-C Drug Product Specification
16.5.3 Astellas Pharmaceuticals IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Abbott Laboratories
16.6.1 Abbott Laboratories Company Profile
16.6.2 Abbott Laboratories IBS-C Drug Product Specification
16.6.3 Abbott Laboratories IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Teva Pharmaceutical Industries
16.7.1 Teva Pharmaceutical Industries Company Profile
16.7.2 Teva Pharmaceutical Industries IBS-C Drug Product Specification
16.7.3 Teva Pharmaceutical Industries IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Novartis Pharma
16.8.1 Novartis Pharma Company Profile
16.8.2 Novartis Pharma IBS-C Drug Product Specification
16.8.3 Novartis Pharma IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Sucampo Pharmaceuticals
16.9.1 Sucampo Pharmaceuticals Company Profile
16.9.2 Sucampo Pharmaceuticals IBS-C Drug Product Specification
16.9.3 Sucampo Pharmaceuticals IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Synthetic Biologics
16.10.1 Synthetic Biologics Company Profile
16.10.2 Synthetic Biologics IBS-C Drug Product Specification
16.10.3 Synthetic Biologics IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Norgine
16.11.1 Norgine Company Profile
16.11.2 Norgine IBS-C Drug Product Specification
16.11.3 Norgine IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Albireo Pharma
16.12.1 Albireo Pharma Company Profile
16.12.2 Albireo Pharma IBS-C Drug Product Specification
16.12.3 Albireo Pharma IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 Bama-Geve
16.13.1 Bama-Geve Company Profile
16.13.2 Bama-Geve IBS-C Drug Product Specification
16.13.3 Bama-Geve IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Astrazeneca
16.14.1 Astrazeneca Company Profile
16.14.2 Astrazeneca IBS-C Drug Product Specification
16.14.3 Astrazeneca IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 Prometheus Laboratories
16.15.1 Prometheus Laboratories Company Profile
16.15.2 Prometheus Laboratories IBS-C Drug Product Specification
16.15.3 Prometheus Laboratories IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 Salix Pharmaceuticals
16.16.1 Salix Pharmaceuticals Company Profile
16.16.2 Salix Pharmaceuticals IBS-C Drug Product Specification
16.16.3 Salix Pharmaceuticals IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 Ferring BV
16.17.1 Ferring BV Company Profile
16.17.2 Ferring BV IBS-C Drug Product Specification
16.17.3 Ferring BV IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 Yuhan Corp
16.18.1 Yuhan Corp Company Profile
16.18.2 Yuhan Corp IBS-C Drug Product Specification
16.18.3 Yuhan Corp IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.19 Actavis Nordic
16.19.1 Actavis Nordic Company Profile
16.19.2 Actavis Nordic IBS-C Drug Product Specification
16.19.3 Actavis Nordic IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.20 Ironwood Pharmaceuticals
16.20.1 Ironwood Pharmaceuticals Company Profile
16.20.2 Ironwood Pharmaceuticals IBS-C Drug Product Specification
16.20.3 Ironwood Pharmaceuticals IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.21 The Menarini Group
16.21.1 The Menarini Group Company Profile
16.21.2 The Menarini Group IBS-C Drug Product Specification
16.21.3 The Menarini Group IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.22 Ono Pharmaceutical
16.22.1 Ono Pharmaceutical Company Profile
16.22.2 Ono Pharmaceutical IBS-C Drug Product Specification
16.22.3 Ono Pharmaceutical IBS-C Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 IBS-C Drug Manufacturing Cost Analysis
17.1 IBS-C Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of IBS-C Drug
17.4 IBS-C Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 IBS-C Drug Distributors List
18.3 IBS-C Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of IBS-C Drug (2021-2026)
20.2 Global Forecasted Revenue of IBS-C Drug (2021-2026)
20.3 Global Forecasted Price of IBS-C Drug (2015-2026)
20.4 Global Forecasted Production of IBS-C Drug by Region (2021-2026)
20.4.1 North America IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America IBS-C Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World IBS-C Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of IBS-C Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of IBS-C Drug by Country
21.2 East Asia Market Forecasted Consumption of IBS-C Drug by Country
21.3 Europe Market Forecasted Consumption of IBS-C Drug by Countriy
21.4 South Asia Forecasted Consumption of IBS-C Drug by Country
21.5 Southeast Asia Forecasted Consumption of IBS-C Drug by Country
21.6 Middle East Forecasted Consumption of IBS-C Drug by Country
21.7 Africa Forecasted Consumption of IBS-C Drug by Country
21.8 Oceania Forecasted Consumption of IBS-C Drug by Country
21.9 South America Forecasted Consumption of IBS-C Drug by Country
21.10 Rest of the world Forecasted Consumption of IBS-C Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer